Recombinant Human CXCL14 Protein，His

CXCL14, also known as BRAK (B-Cell Recruitment Activator Kit), is a chemokine that plays a significant role in regulating immune responses and has been implicated in various pathological conditions, including cancer and inflammatory diseases. It primarily functions by attracting immune cells, such as dendritic cells and T lymphocytes, thus influencing the recruitment and activation of these cells in the tumor microenvironment. Recent studies have highlighted the dual role of CXCL14 in cancer, where it can exhibit tumor-suppressive properties by inhibiting tumor growth and metastasis, yet it may also facilitate tumor progression under certain conditions. This has sparked interest in its potential therapeutic applications, as CXCL14 could be harnessed for immunotherapy strategies. The production of recombinant CXCL14 protein allows for detailed investigations into its biochemical properties, signaling pathways, and interactions with immune cells. Furthermore, understanding the structure-function relationship of CXCL14 can provide insights into its mechanisms of action, paving the way for the development of novel interventions in diseases characterized by dysregulated immune responses. Ongoing research aims to elucidate the complex roles of CXCL14 in the immune landscape, with the hope of translating these findings into innovative therapeutic options that enhance immune responses against tumors or regulate chronic inflammation.